METUPUK are disappointed by the National Institute of Clinical Excellence (NICE) decision to not recommend talazoparib (Talzenna ®, Pfizer Ltd.) for treating HER2-negative, locally advanced or metastatic breast cancer with
Seagen Biotech company asked two metastatic breast cancer (MBC) advocates Eva Schumacher from Mamma Mia online German cancer magazine and patient living with MBC and myself Jo Taylor founder of
METUPUK are delighted by the Scottish Medicines Consortium (SMC) acceptance of Enhertu (trastuzumab deruxtecan) for routine use on the NHS. The Scottish Medicines Consortium (SMC) has accepted: Trastuzumab deruxtecan (Enhertu)
METUPUK are devastated by the news that one of our Trustees and friend Connie Johncock has died. Connie was a founder trustee of METUPUK and our Treasurer, overseeing our finances as we
Stage 4 breast cancer with a pacemaker
Most people know someone with a pacemaker, and chances are that person will be elderly. The average age of a first pacemaker implantation in the UK is 72, but pacemakers are actually fitted in people of all ages from newborn babies to the very elderly. I was 39 when I had mine, which was needed as a complication after heart surgery to replace my aortic valve and root.
13th October is officially Secondary Breast Cancer day – the only day in Breast Cancer Awareness Month that officially recognises secondary (metastatic) breast cancer (download as PDF). And so, this
The terminology around cancer can be confusing, and no more so than for Stage IV cancer. The terms ‘secondary’, ‘advanced’ and ‘metastatic’ seem to be used fairly interchangeably, along with
#IAmThe31 31 women die every day in the UK is our reality. This campaign is for October Breast Cancer Awareness Month. 31 days in October, 31 deaths every day, by
What’s your postcode and what does that say about you? If I asked a healthy person about the importance of their postcode I suspect they’d tell me about local schools,
Hi my name is Kit and apparently I’m a stubborn cow! Now the person who told me that didn’t think it was a good thing. But for a secondary breast
